The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...

Dawn L. Hershman, MD, MS, will present work at SABCS 2023 that uses baseline sociodemographic and financial measures to predict which patients prescribed long-term therapy with aromatase inhibitors ...

The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.

The FDA approval was based on NATALEE, a randomized (1:1), open-label, multicenter, multinational trial in adults of any sex or menopausal status with hormone receptor–positive, HER2-negative stage II ...

CHICAGO (Reuters) - U.S. researchers may have found a way to overcome resistance to hormone-blocking breast cancer drugs, extending the life of treatments that keep the disease in check. They said the ...

Aromatase inhibitors (AIs) represent a cornerstone in the treatment of oestrogen receptor–positive breast cancer, particularly among postmenopausal women. Although these drugs have substantially ...

Postmenopausal women can use alternative drugs known as aromatase inhibitors, but those are not an option for younger ...

The U.S. Food and Drug Administration (FDA) has approved Inluriyo (imlunestrant) for the treatment of adults with estrogen ...

These Phase III results could enhance Verzenio’s uptake alongside ET in the adjuvant breast cancer setting, if approved.